Plasma neurodegeneration biomarkers and clinical progression in early sporadic Parkinson's disease
Objectives: Plasma neurodegeneration biomarkers offer an opportunity to characterize Parkinson's disease (PD) biology. The objective of this study was to investigate such biomarkers in deeply-phenotyped participants in Parkinson's Precision Medicine Initiative (PPMI). Methods: Baseline plasma samples from early (<2 years since diagnosis) sporadic PD participants with a positive CSF alpha-synuclein seed amplification assay (aSyn-SAA) and healthy controls (HC) with a negative aSyn-SAA test were utilized. Plasma P-tau217 (Roche Diagnostics), neurofilament light chain (NfL, Quanterix), glial fibrillary acidic protein (GFAP, Quanterix), and (PD only) amyloid-beta (Aβ) levels (40 and 42, C2N Diagnostics) were measured. Clinical features at baseline and over up to 11 years were compared across biomarker tertiles in models controlling for age, sex, and baseline outcome variable. Results: The cohort was 97 HC and 523 PD and participants. Median [IQR] biomarker values (pg/mL) for HC and PD were P-tau217: 0.14 [0.06 -0.75], 0.15 [0.06 -0.90]; NfL: 10.6 [3.13 -49.85], 12.26 [3.77-62.67]; GFAP: 66.56 [19.75 -403.48], 87.19 [14.55 -531.82]; and in PD Aβ40: 391.32 [209.95 -538.38]; Aβ42: 42.74[27.75 -68.55]. No biomarkers differed between HC and PD. In PD, biomarkers were associated with age. In PD only, higher baseline levels of P-tau217 and NfL were associated with greater hazards of a worse cognitive and balance outcome. P-tau217, NfL, and GFAP levels were associated with change in cognitive score over time. Interpretation: Plasma P-tau217, NfL and GFAP levels in early, sporadic PD with confirmed synucleinopathy predict future cognitive and functional impairment, and these findings can inform clinical research design and clinical care.
Authors
- Kristopher M. Kirmess (ORCID: https://orcid.org/0000-0002-0306-323X)
- Thomas Francis Tropea (ORCID: https://orcid.org/0000-0003-0766-1496)
- Tim West (ORCID: https://orcid.org/0000-0003-3267-8249)
- Ming Lü (ORCID: https://orcid.org/0000-0002-8685-6322)
- David G. Coughlin (ORCID: https://orcid.org/0000-0003-4111-0102)
- Kristen A. Russ
- Leonardo Iaccarino (ORCID: https://orcid.org/0000-0003-0053-9519)
- Sarah M. Brooker (ORCID: https://orcid.org/0000-0002-5674-3124)
- Javier E. Flores (ORCID: https://orcid.org/0000-0002-1550-1655)
- Christopher S. Coffey (ORCID: https://orcid.org/0000-0002-8130-5484)
- Tatiana Foroud
- Tanya Simuni
- Krittika Chatterjee
- Anuprita Nair (ORCID: https://orcid.org/0009-0008-6067-1531)
- Daniel Weintraub
- Noah S. Johnson
- Amanda Morris
- the Parkinson's Precision Medicine Initiative
- David-Erick Lafontant
- Matthew Flitter
- Philip B. Verghese
- Rose Beck
- Kenneth Marek
- Micah Marshall
- Patricia Aldea-Stevenson
- Lana M. Chahine
- Samantha Hutten
- Kalpana Merchant
Institutions
- Northwestern University (US)
- University of Iowa (US)
- Eli Lilly (United States) (US)
- University of California, San Francisco (US)
- Michael J. Fox Foundation (US)
- University of California System (US)
- University of California San Diego (US)
- C2N Diagnostics (United States) (US)
- Institute for Neurodegenerative Disorders (US)
- Indiana University Indianapolis (US)
- Indiana University School of Medicine (US)
- University of Pennsylvania (US)
Publication Details
- Journal
- medRxiv
- Published
- 2026-11-20
- DOI
- https://doi.org/10.64898/2026.11.18.26368420
- Primary Topic
- Parkinson's Disease Mechanisms and Treatments
- Type
- preprint